InspireMD, Inc. reported its financial results for the first quarter ended March 31, 2025, on May 9, 2025. Total revenue for the quarter increased by 1.2% to $1.529 million compared to $1.511 million in Q1 2024, driven by continued adoption in existing international markets.
Gross profit remained flat at $292,000 year-over-year, while total operating expenses increased significantly by 52.5% to $11.752 million. This rise was primarily due to higher salaries, share-based compensation for U.S. sales force expansion, CGuard Prime launch preparation, and U.S. facility rent.
The net loss for Q1 2025 widened to $11.166 million, or $0.22 per share, compared to $7.032 million, or $0.21 per share, in Q1 2024. As of March 31, 2025, cash and marketable securities totaled $26.086 million.
CEO Marvin Slosman stated that the company continues to work interactively with the FDA and is optimistic for an anticipated approval of CGuard Prime in the third quarter of 2025, a revision from the previously anticipated first half of 2025. This updated timeline is attributed to the scheduling and follow-up required from a facility site audit.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.